3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
13
Hodgkin Disease
11
Lymphoma, Non-Hodgkin
10
Lymphoma, Large B-Cell, Diffuse
10
Lymphoma, Follicular
10
Lymphoma, Mantle-Cell
9
Lymphoma
9
Leukemia, Lymphocytic, Chronic, B-Cell
7
Recurrence
6
Lymphoma, B-Cell
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia
3
Immune System Diseases
3
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Neoplasms, Plasma Cell
2
Neoplasms
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Extranodal NK-T-Cell
2
Leukemia, Myeloid, Acute
2
Burkitt Lymphoma
2
Breast Neoplasms
2
Waldenstrom Macroglobulinemia
1
Squamous Cell Carcinoma of Head and Neck
1
Sezary Syndrome
1
Sarcoma
1
Proteostasis Deficiencies
1
Interventions
ibrutinib
2
Bortezomib
2
ponatinib
1
fludarabine phosphate
1
fludarabine
1
enzalutamide
1
durvalumab
1
blinatumomab
1
Rituximab
1
Lenalidomide
1
KW-2478
1
Hsp90 inhibitor KU757
1
Cyclophosphamide
1
CA-4948
1
Bendamustine Hydrochloride
1
ARQ531
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Immunoproliferative Disorders
×
Bendamustine Hydrochloride
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts